Impax Laboratories has again been tripped up by labeling issues on a drug and is retrieving a lot of a med for treating epilepsy or bipolar disorders in its most recent recall.
Eli Lilly and Boehringer Ingelheim got the verdict they were looking for Tuesday on a Jardiance label addition. But the vote was closer than the pair would have liked.
Every drugmaker wants to find differentiators for their products. And for Ironwood ($IRWD), it was obvious. Is this a constipation drug that improves abdominal symptoms, or is this an abdominal...